Pharmathene(PIP)

0 %

简介:Altimmune, Inc.于2005年4月25日根据特拉华州法律成立。Altimmune, Inc.是一家临床阶段的生物制药公司,专注于开发肥胖和肝病的治疗方法。他们的主要候选产品pemvidutide(以前称为ALT-801)是一种GLP-1/胰高血糖素双受体激动剂,正在开发用于治疗肥胖和代谢功能障碍相关的脂肪性肝炎(“MASH”),以前称为非酒精性脂肪性肝炎。


公司网站:
公司地址:910 Clopper Road Suite 201S Gaithersburg MD 20878
公司电话:1-240-6541450
今开:昨收:0
最高:最低:
涨停价:跌停价:
总市值:48514700

Pharmathene的最新讨论

Pharmathene的公告

公告

$Pharmathene(PIP)$ 8-K - Current report Filed: 2019-10-01 AccNo: 0001193125-19-259847 Size: 38 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 5.07: Submission o...

公告

$Pharmathene(PIP)$ 8-K - Current report Filed: 2019-08-21 AccNo: 0001193125-19-225595 Size: 34 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接

公告

$Pharmathene(PIP)$ 8-K - Current report Filed: 2019-08-13 AccNo: 0001564590-19-031811 Size: 395 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

公告

$Pharmathene(PIP)$ 8-K - Current report Filed: 2019-07-15 AccNo: 0001193125-19-193586 Size: 39 KBItem 2.01: Completion of Acquisition or Disposition of AssetsItem 3.02: Unregistered Sales of Equity SecuritiesItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements a...

公告

$Pharmathene(PIP)$ 8-K - Current report Filed: 2019-07-09 AccNo: 0001193125-19-190926 Size: 7 MBItem 1.01: Entry into a Material Definitive AgreementItem 3.02: Unregistered Sales of Equity SecuritiesItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibi...